Merck's phase 3 KEYNOTE─B96 trial meet primary endpoint of PFS in patients with platinum─resistant recurrent ovarian ...
Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent …